Technology | October 11, 2012

Boston Scientific Launches Victory Guidewire For Crossing Resistant Peripheral Lesions

Victory guidewires are designed to facilitate crossing of resistant lesions

Boston Scientific Victory Crosswire Peripheral Artery Disease

October 11, 2012 — Boston Scientific Corporation has begun the U.S. and European launch of its Victory guidewire, designed to facilitate crossing of resistant lesions and the placement and exchange of balloon catheters or other interventional devices within the peripheral vasculature.  The company expects to launch the product in other international markets later this year and in 2013, subject to regulatory approvals.

An estimated 17.6 million Americans suffer from peripheral artery disease, which is characterized by blockage or narrowing in vessels of the peripheral vasculature, frequently associated with high rates of morbidity and mortality.  Critical limb ischemia (CLI) is a serious condition affecting an increasing number of patients worldwide.  CLI patients have multi-vessel disease and challenging lesions, which, if left untreated, can lead to limb loss.  In the United States, an estimated 25 percent of patients with peripheral artery disease will require amputation within one year of onset of CLI.  Saving limbs through surgery or endovascular techniques improves the quality of life for patients.

"Resistant lesions can be a challenge and I often need various tools to access, cross and treat these types of lesions," said Derek Mittleider, M.D., interventional radiologist, director, vascular and interventional radiology, Spectrum Medical Group.  "The Victory wire's high gram-load options and excellent torque-ability give me the extra push and steer-ability I need to get through these resistant lesions more easily, making these cases less challenging."

The Victory guidewires feature a broad matrix of high gram-load tip options ranging from 12 grams to 30 grams, designed to cross-resistant lesions.  A unique stainless steel core technology enables this wire to have superior torque for optimal steering and control.  Hydrophilic coating provides enhanced lubricity to facilitate crossing resistant lesions.  The Victory guidewires come in both 0.014-inch and 0.018-inch diameters with four different gram-load options offering clinical versatility and a range of pushability.

"Physicians treating CLI patients typically require a variety of treatment options. Boston Scientific is committed to offering a wide variety of crossing solutions," said Jeff Mirviss, president of the Boston Scientific Peripheral Interventions Division.  "Victory guidewires complement our already broad portfolio of crossing solutions, inclusive of our market-leading angioplasty balloons, Rubicon Support Catheter and the TruePath CTO device. The Victory guidewires offer another option to cross these highly resistant lesions and potentially avoid the need for amputation."

For more information:



Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init